<html lang="en">
<head>
<meta charset="utf-8"/>
<title offset="639">Bioavailability</title>
<script src="https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_SVG.js" type="text/javascript">
</script>
</head>
<body>
<h1>Bioavailability</h1>
<hr/>

<p>In <a class="uri" href="pharmacology" title="wikilink">pharmacology</a>, <strong>bioavailability</strong> (<strong>BA</strong>) is a subcategory of absorption and is the fraction of an administered <a href="Dose_(biochemistry)" title="wikilink">dose</a> of unchanged drug that reaches the <a href="systemic_circulation" title="wikilink">systemic circulation</a>, one of the principal <a href="pharmacokinetics" title="wikilink">pharmacokinetic</a> properties of <a href="medication" title="wikilink">drugs</a>. By definition, when a medication is administered <a href="intravenous" title="wikilink">intravenously</a>, its bioavailability is 100%.<a class="footnoteRef" href="#fn1" id="fnref1"><sup>1</sup></a> However, when a medication is administered via other <a href="route_of_administration" title="wikilink">routes</a> (such as orally), its bioavailability generally decreases (due to incomplete absorption and <a href="first-pass_metabolism" title="wikilink">first-pass metabolism</a>) or may vary from patient to patient. Bioavailability is one of the essential tools in pharmacokinetics, as bioavailability must be considered when calculating dosages for non-intravenous routes of administration.</p>

<p>For <a href="dietary_supplements" title="wikilink">dietary supplements</a>, herbs and other nutrients in which the route of administration is nearly always oral, bioavailability generally designates simply the quantity or fraction of the ingested dose that is absorbed.<a class="footnoteRef" href="#fn2" id="fnref2"><sup>2</sup></a></p>

<p>Bioavailability is defined slightly differently for drugs as opposed to <a href="dietary_supplements" title="wikilink">dietary supplements</a> primarily due to the method of administration and <a href="Food_and_Drug_Administration" title="wikilink">Food and Drug Administration</a> regulations.</p>

<p><strong>Bioaccessibility</strong> is a concept related to bioavailability in the context of <a class="uri" href="biodegradation" title="wikilink">biodegradation</a> and <a href="environmental_pollution" title="wikilink">environmental pollution</a>. A <a class="uri" href="molecule" title="wikilink">molecule</a> (often a <a href="persistent_organic_pollutant" title="wikilink">persistent organic pollutant</a>) is said to be bioaccessible when "[it] is available to cross an organism's <a href="cellular_membrane" title="wikilink">cellular membrane</a> from the environment, if the organism has access to the chemical."<a class="footnoteRef" href="#fn3" id="fnref3"><sup>3</sup></a></p>
<h2 id="definitions">Definitions</h2>
<h3 id="in-pharmacology">In pharmacology</h3>

<p>In pharmacology, bioavailability is a measurement of the rate and extent to which a drug reaches at the site of action. .<a class="footnoteRef" href="#fn4" id="fnref4"><sup>4</sup></a> It is denoted by the letter <em>f</em> (or, if expressed in percent, by <em>F</em>).</p>
<h3 id="in-nutritional-sciences">In nutritional sciences</h3>

<p>In nutritional sciences, which covers the intake of nutrients and non-drug dietary ingredients, the concept of bioavailability lacks the well-defined standards associated with the pharmaceutical industry. The pharmacological definition cannot apply to these substances because utilization and absorption is a function of the nutritional status and physiological state of the subject,<a class="footnoteRef" href="#fn5" id="fnref5"><sup>5</sup></a> resulting in even greater differences from individual to individual (inter-individual variation). Therefore, bioavailability for dietary supplements can be defined as the proportion of the administered substance capable of being absorbed and available for use or storage.<a class="footnoteRef" href="#fn6" id="fnref6"><sup>6</sup></a></p>

<p>In both pharmacology and nutrition sciences, bioavailability is measured by calculating the <a href="area_under_curve" title="wikilink">area under curve</a> (AUC) of the drug concentration time profile.</p>
<h3 id="in-environmental-sciences">In environmental sciences</h3>

<p>Bioavailability is commonly a limiting factor in the production of crops (due to solubility limitation or adsorption of plant nutrients to soil colloids) and in the removal of toxic substances from the food chain by microorganisms (due to sorption to or partitioning of otherwise degradable substances into inaccessible phases in the environment). A noteworthy example for agriculture is plant phosphorus deficiency induced by precipitation with iron and aluminum phosphates at low soil pH and precipitation with calcium phosphates at high soil pH.<a class="footnoteRef" href="#fn7" id="fnref7"><sup>7</sup></a> Toxic materials in soil, such as lead from paint may be rendered unavailable to animals ingesting contaminated soil by supplying phosphorus fertilizers in excess.<a class="footnoteRef" href="#fn8" id="fnref8"><sup>8</sup></a> Organic pollutants such as solvents or pesticides<a class="footnoteRef" href="#fn9" id="fnref9"><sup>9</sup></a> may be rendered unavailable to microorganisms and thus persist in the environment when they are adsorbed to soil minerals<a class="footnoteRef" href="#fn10" id="fnref10"><sup>10</sup></a> or partition into hydrophobic organic matter.<a class="footnoteRef" href="#fn11" id="fnref11"><sup>11</sup></a></p>
<h2 id="absolute-bioavailability">Absolute bioavailability</h2>
<figure><b>(Figure)</b>
<figcaption>Absolute bioavailability is a ratio of areas under the curves. IV, intravenous; PO, oral route.</figcaption>
</figure>

<p>Absolute bioavailability compares the bioavailability of the active drug in systemic circulation following non-<a class="uri" href="intravenous" title="wikilink">intravenous</a> <a href="route_of_administration" title="wikilink">administration</a> (i.e., after <a href="per_os" title="wikilink">oral</a>, rectal, <a class="uri" href="transdermal" title="wikilink">transdermal</a>, <a href="Subcutaneous_injection" title="wikilink">subcutaneous</a>, or <a class="uri" href="sublingual" title="wikilink">sublingual</a> administration), with the bioavailability of the same drug following intravenous administration. It is the fraction of the drug absorbed through non-intravenous administration compared with the corresponding intravenous administration of the same drug. The comparison must be dose normalized (e.g., account for different doses or varying weights of the subjects); consequently, the amount absorbed is corrected by dividing the corresponding dose administered.</p>

<p>In pharmacology, in order to determine absolute bioavailability of a drug, a <a class="uri" href="pharmacokinetic" title="wikilink">pharmacokinetic</a> study must be done to obtain a <em>plasma drug concentration vs time</em> plot for the drug after both intravenous (iv) and extravascular (non-intravenous, i.e., oral) administration. The absolute bioavailability is the dose-corrected area under curve (AUC) non-intravenous divided by AUC intravenous. For example, the formula for calculating <em>F</em> for a drug administered by the oral route (po) is given below.</p>

<p>

<math display="block" id="Bioavailability:0">
 <semantics>
  <mrow>
   <msub>
    <mi>F</mi>
    <mrow>
     <mi>a</mi>
     <mi>b</mi>
     <mi>s</mi>
    </mrow>
   </msub>
   <mo>=</mo>
   <mrow>
    <mn>100</mn>
    <mo>⋅</mo>
    <mfrac>
     <mrow>
      <mrow>
       <mi>A</mi>
       <mi>U</mi>
       <msub>
        <mi>C</mi>
        <mrow>
         <mi>p</mi>
         <mi>o</mi>
        </mrow>
       </msub>
      </mrow>
      <mo>⋅</mo>
      <msub>
       <mi>D</mi>
       <mrow>
        <mi>i</mi>
        <mi>v</mi>
       </mrow>
      </msub>
     </mrow>
     <mrow>
      <mrow>
       <mi>A</mi>
       <mi>U</mi>
       <msub>
        <mi>C</mi>
        <mrow>
         <mi>i</mi>
         <mi>v</mi>
        </mrow>
       </msub>
      </mrow>
      <mo>⋅</mo>
      <msub>
       <mi>D</mi>
       <mrow>
        <mi>p</mi>
        <mi>o</mi>
       </mrow>
      </msub>
     </mrow>
    </mfrac>
   </mrow>
  </mrow>
  <annotation-xml encoding="MathML-Content">
   <apply>
    <eq></eq>
    <apply>
     <csymbol cd="ambiguous">subscript</csymbol>
     <ci>F</ci>
     <apply>
      <times></times>
      <ci>a</ci>
      <ci>b</ci>
      <ci>s</ci>
     </apply>
    </apply>
    <apply>
     <ci>normal-⋅</ci>
     <cn type="integer">100</cn>
     <apply>
      <divide></divide>
      <apply>
       <ci>normal-⋅</ci>
       <apply>
        <times></times>
        <ci>A</ci>
        <ci>U</ci>
        <apply>
         <csymbol cd="ambiguous">subscript</csymbol>
         <ci>C</ci>
         <apply>
          <times></times>
          <ci>p</ci>
          <ci>o</ci>
         </apply>
        </apply>
       </apply>
       <apply>
        <csymbol cd="ambiguous">subscript</csymbol>
        <ci>D</ci>
        <apply>
         <times></times>
         <ci>i</ci>
         <ci>v</ci>
        </apply>
       </apply>
      </apply>
      <apply>
       <ci>normal-⋅</ci>
       <apply>
        <times></times>
        <ci>A</ci>
        <ci>U</ci>
        <apply>
         <csymbol cd="ambiguous">subscript</csymbol>
         <ci>C</ci>
         <apply>
          <times></times>
          <ci>i</ci>
          <ci>v</ci>
         </apply>
        </apply>
       </apply>
       <apply>
        <csymbol cd="ambiguous">subscript</csymbol>
        <ci>D</ci>
        <apply>
         <times></times>
         <ci>p</ci>
         <ci>o</ci>
        </apply>
       </apply>
      </apply>
     </apply>
    </apply>
   </apply>
  </annotation-xml>
  <annotation encoding="application/x-tex">
   F_{abs}=100\cdot\frac{AUC_{po}\cdot D_{iv}}{AUC_{iv}\cdot D_{po}}
  </annotation>
 </semantics>
</math>

</p>

<p>Therefore, a drug given by the intravenous route will have an absolute bioavailability of 100% (<em>f</em>=1), whereas drugs given by other routes usually have an absolute bioavailability of less than one. If we compare the two different dosage forms having same active ingredients and compare the two drug bioavailability is called comparative bioavailability.</p>

<p>Although knowing the true extent of systemic absorption (referred to as absolute bioavailability) is clearly useful, in practice it is not determined as frequently as one may think. The reason for this is that its assessment requires an intravenous reference, that is, a route of administration that guarantees that all of the administered drug reaches the systemic circulation. Such studies come at considerable cost, not least of which is the necessity to conduct preclinical toxicity tests to ensure adequate safety, as well as there being potential problems due to solubility limitations. These limitations may be overcome, however, by administering a very low dose (typically a few micrograms) of an isotopically labelled drug concomitantly with a therapeutic non-labelled oral dose. Providing the isotopically-labelled intravenous dose is sufficiently low so as not to perturb the systemic drug concentrations achieved from the absorbed oral dose, then the intravenous and oral pharmacokinetics can be deconvoluted by virtue of the their different isotopic constitution and thereby determine the oral and intravenous pharmacokinetics from the same dose administration. This technique eliminates pharmacokinetic issues on non-equivalent clearance as well as enabling the intravenous dose to be administered with a minimum of toxicology and formulation. The technique was first applied using stable-isotopes such as C-13 and mass-spectrometry to distinguish the isotopes by mass difference. More recently, C-14 labelled drugs are administered intravenously and accelerator mass spectrometry (AMS) used to measure the isotopically labelled drug along with mass spectrometry for the unlabelled drug.<a class="footnoteRef" href="#fn12" id="fnref12"><sup>12</sup></a></p>

<p>There is no regulatory requirement to define the intravenous pharmacokinetics or absolute bioavailability however regulatory authorities do sometimes ask for absolute bioavailability information of the extravascular route in cases in which the bioavailability is apparently low or variable and there is a proven relationship between the <a class="uri" href="pharmacodynamics" title="wikilink">pharmacodynamics</a> and the pharmacokinetics at therapeutic doses. In all such cases, to conduct an absolute bioavailability study requires that the drug be given intravenously.<a class="footnoteRef" href="#fn13" id="fnref13"><sup>13</sup></a></p>

<p>Intravenous administration of a developmental drug can provide valuable information on the fundamental pharmacokinetic parameters of <a href="volume_of_distribution" title="wikilink">volume of distribution</a> (V) and <a href="Clearance_(medicine)" title="wikilink">clearance</a> (CL).<a class="footnoteRef" href="#fn14" id="fnref14"><sup>14</sup></a></p>
<h2 id="relative-bioavailability-and-bioequivalence">Relative bioavailability and bioequivalence</h2>

<p>In pharmacology, relative bioavailability measures the bioavailability (estimated as the AUC) of a formulation (<em>A</em>) of a certain drug when compared with another formulation (<em>B</em>) of the same drug, usually an established standard, or through administration via a different route. When the standard consists of intravenously administered drug, this is known as absolute bioavailability (see <a href="#Absolute_bioavailability" title="wikilink">above</a>).</p>

<p>

<math display="block" id="Bioavailability:1">
 <semantics>
  <mrow>
   <msub>
    <mi>F</mi>
    <mrow>
     <mi>r</mi>
     <mi>e</mi>
     <mi>l</mi>
    </mrow>
   </msub>
   <mo>=</mo>
   <mrow>
    <mn>100</mn>
    <mo>⋅</mo>
    <mfrac>
     <mrow>
      <mrow>
       <mi>A</mi>
       <mi>U</mi>
       <msub>
        <mi>C</mi>
        <mi>A</mi>
       </msub>
      </mrow>
      <mo>⋅</mo>
      <msub>
       <mi>D</mi>
       <mi>B</mi>
      </msub>
     </mrow>
     <mrow>
      <mrow>
       <mi>A</mi>
       <mi>U</mi>
       <msub>
        <mi>C</mi>
        <mi>B</mi>
       </msub>
      </mrow>
      <mo>⋅</mo>
      <msub>
       <mi>D</mi>
       <mi>A</mi>
      </msub>
     </mrow>
    </mfrac>
   </mrow>
  </mrow>
  <annotation-xml encoding="MathML-Content">
   <apply>
    <eq></eq>
    <apply>
     <csymbol cd="ambiguous">subscript</csymbol>
     <ci>F</ci>
     <apply>
      <times></times>
      <ci>r</ci>
      <ci>e</ci>
      <ci>l</ci>
     </apply>
    </apply>
    <apply>
     <ci>normal-⋅</ci>
     <cn type="integer">100</cn>
     <apply>
      <divide></divide>
      <apply>
       <ci>normal-⋅</ci>
       <apply>
        <times></times>
        <ci>A</ci>
        <ci>U</ci>
        <apply>
         <csymbol cd="ambiguous">subscript</csymbol>
         <ci>C</ci>
         <ci>A</ci>
        </apply>
       </apply>
       <apply>
        <csymbol cd="ambiguous">subscript</csymbol>
        <ci>D</ci>
        <ci>B</ci>
       </apply>
      </apply>
      <apply>
       <ci>normal-⋅</ci>
       <apply>
        <times></times>
        <ci>A</ci>
        <ci>U</ci>
        <apply>
         <csymbol cd="ambiguous">subscript</csymbol>
         <ci>C</ci>
         <ci>B</ci>
        </apply>
       </apply>
       <apply>
        <csymbol cd="ambiguous">subscript</csymbol>
        <ci>D</ci>
        <ci>A</ci>
       </apply>
      </apply>
     </apply>
    </apply>
   </apply>
  </annotation-xml>
  <annotation encoding="application/x-tex">
   F_{rel}=100\cdot\frac{AUC_{A}\cdot D_{B}}{AUC_{B}\cdot D_{A}}
  </annotation>
 </semantics>
</math>

</p>

<p>Relative bioavailability is one of the measures used to assess <a class="uri" href="bioequivalence" title="wikilink">bioequivalence</a> (BE) between two drug products. For FDA approval, a generic manufacturer must demonstrate that the 90% <a href="confidence_interval" title="wikilink">confidence interval</a> for the ratio of the mean responses (usually of AUC and the maximum concentration, C<sub>max</sub>) of its product to that of the "Brand Name drug" is within the limits of 80% to 125%. While AUC refers to the extent of bioavailability, C<sub>max</sub> refers to the rate of bioavailability. When T<sub>max</sub> is given, it refers to the time it takes for a drug to reach C<sub>max</sub>.</p>

<p>While the mechanisms by which a formulation affects bioavailability and bioequivalence have been extensively studied in drugs, formulation factors that influence bioavailability and bioequivalence in nutritional supplements are largely unknown.<a class="footnoteRef" href="#fn15" id="fnref15"><sup>15</sup></a> As a result, in nutritional sciences, relative bioavailability or bioequivalence is the most common measure of bioavailability, comparing the bioavailability of one formulation of the same dietary ingredient to another.</p>
<h2 id="factors-influencing-bioavailability">Factors influencing bioavailability</h2>

<p>The absolute bioavailability of a drug, when administered by an extravascular route, is usually less than one (i.e., <em>F</em> </p>

<p>In addition, the lack of defined methodology and regulations surrounding the consumption of dietary supplements hinders the application of bioavailability measures in comparison to drugs. In clinical trials with dietary supplements, bioavailability primarily focuses on statistical descriptions of mean or average AUC differences between treatment groups, while often failing to compare or discuss their standard deviations or inter-individual variation. This failure leaves open the question of whether or not an individual in a group is likely to experience the benefits described by the mean-difference comparisons. Further, even if this issue were discussed, it would be difficult to communicate meaning of these inter-subject variances to consumers and/or their physicians.</p>
<h2 id="nutritional-science-reliable-and-universal-bioavailability">Nutritional science: reliable and universal bioavailability</h2>

<p>One way to resolve this problem is to define "reliable bioavailability" as positive bioavailability results (an absorption meeting a predefined criteria) that include 84% of the trial subjects and "universal bioavailability" as those that include 98% of the trial subjects. This reliable-universal framework would improve communications with physicians and consumers such that, if it were included on products labels for example, make educated choices as to the benefits of a formulation for them directly. In addition, the reliable-universal framework is similar to the construction of confidence intervals, which statisticians have long offered as one potential solution for dealing with small samples, violations of statistical assumptions or large standard deviations.<a class="footnoteRef" href="#fn16" id="fnref16"><sup>16</sup></a></p>
<h2 id="see-also">See also</h2>
<ul>
<li><a class="uri" href="ADME-Tox" title="wikilink">ADME-Tox</a></li>
<li><a href="Lipinski's_Rule_of_5" title="wikilink">Lipinski's Rule of 5</a></li>
<li><a href="Biopharmaceutics_Classification_System" title="wikilink">Biopharmaceutics Classification System</a></li>
<li><a class="uri" href="Caco-2" title="wikilink">Caco-2</a></li>
</ul>
<h2 id="notes">Notes</h2>

<p><mtpl></mtpl> </p>
<h2 id="references">References</h2>
<h2 id="sources">Sources</h2>
<ul>
<li></li>
<li></li>
<li></li>
<li></li>
</ul>
<h2 id="external-links">External links</h2>
<ul>
<li><a href="http://www.boomer.org/c/p4/c07/c0701.html">Routes of Drug Administration</a></li>
<li><a href="http://howmed.net/pharmacology/bioavailability-of-drugs/">Bioavailability of Drugs</a></li>
</ul>

<p>"</p>

<p><a class="uri" href="Category:Pharmacokinetics" title="wikilink">Category:Pharmacokinetics</a> <a href="Category:Medicinal_chemistry" title="wikilink">Category:Medicinal chemistry</a> <a href="Category:Life_sciences_industry" title="wikilink">Category:Life sciences industry</a></p>
<section class="footnotes">
<hr/>
<ol>
<li id="fn1">Griffin, J.P. The Textbook of Pharmaceutical Medicine (6th Ed.). New Jersey: BMJ Books. ISBN 978-1-4051-8035-1<a href="#fnref1">↩</a></li>
<li id="fn2"><a href="#fnref2">↩</a></li>
<li id="fn3"><a href="#fnref3">↩</a></li>
<li id="fn4">Shargel, L.; Yu, A.B. (1999). <em>Applied biopharmaceutics &amp; pharmacokinetics</em> (4th ed.). New York: McGraw-Hill. ISBN 0-8385-0278-4<a href="#fnref4">↩</a></li>
<li id="fn5"><a href="#fnref5">↩</a></li>
<li id="fn6"><a href="#fnref6">↩</a></li>
<li id="fn7"><a href="#fnref7">↩</a></li>
<li id="fn8"><a href="#fnref8">↩</a></li>
<li id="fn9"><a href="#fnref9">↩</a></li>
<li id="fn10"><a href="#fnref10">↩</a></li>
<li id="fn11"><a href="#fnref11">↩</a></li>
<li id="fn12"><a href="#fnref12">↩</a></li>
<li id="fn13"><a href="#fnref13">↩</a></li>
<li id="fn14"></li>
<li id="fn15"><a href="#fnref15">↩</a></li>
<li id="fn16"><a href="#fnref16">↩</a></li>
</ol>
</section>
</body>
</html>
